Jounce Therapeutics Inc
JNCE
Get informed when a big investor buys or sells
+ FollowCurrent Fair Value
101.8% upsideUndervalued by 101.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $98.95 Million |
|---|---|
| Enterprise Value | $-41,597,260.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.99 |
| Beta | 0.75 |
| Outstanding Shares | 51,676,000 |
Return
| Return on Equity | -27.81% |
|---|---|
| Return on Assets | -23.96% |
| Return on Invested Capital | -27.64% |
Valuation & Multiples
| P/E Ratio | -1.91 |
|---|---|
| PEG | 0 |
| Price to Sales | 1.88 |
| Price to Book Ratio | 0.63 |
| Enterprise Value to Revenue | -0.51 |
| Enterprise Value to EBIT | 0.8 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | -0.24 |
| Debt to Equity | 0.05 |
Revenue Sources
No data
Insider Trades
Institutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Jounce Therapeutics Inc
CEO: Richard Murray Relevant Senate Committees
Controls Medicare and Medicaid reimbursement rates and tax policy, both of which are critical for the commercial success and R&D funding of biotech firms.
Determines the funding levels for the FDA and NIH; these allocations directly impact the speed and availability of drug reviews and federal research grants.
Directly oversees the FDA and NIH; this committee's decisions on drug approval processes and clinical trial regulations are material to the company.
Oversees patent law and intellectual property rights, which are the primary assets and value drivers for any biological manufacturing company.